Business Context and Reporting Period
Company: Aligos Therapeutics, Inc. (ALGS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Aligos is a clinical-stage biotechnology company developing novel therapeutics for liver and viral diseases, specifically chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company has no products approved for commercial sale and has incurred significant losses since inception.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $30,608 | $1,276 |
| Revenue from Licensing Agreements | $27,778 | $0 |
| Revenue from Customers | $2,830 | $1,276 |
| Total Operating Expenses | $59,427 | $39,086 |
| Research and Development (R&D) | $47,402 | $28,478 |
| General and Administrative (G&A) | $12,025 | $10,608 |
| Net Loss | $(24,544) | $27,225 (Income) |
| Cash and Cash Equivalents (End of Period) | $30,381 | $18,771 |
| Accumulated Deficit | $(666,745) | $(590,783) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased significantly to $30.6 million for the six months ended June 30, 2026, compared to $1.3 million in the prior year. This was driven primarily by a $27.8 million upfront payment recognized from a new license agreement with Xiamen Amoytop Biotech Co., Ltd. (Amoytop) for the development and commercialization of pevifoscorvir sodium in Greater China.
- Operating Expenses: Total operating expenses rose 52% to $59.4 million. R&D expenses increased by $18.9 million (66%) due to increased clinical study costs for the Phase 2 B-SUPREME trial of pevifoscorvir sodium.
- Net Income to Loss: The company reported a net loss of $24.5 million for the six months ended June 30, 2026, compared to net income of $27.2 million in the same period in 2025. The prior year's income was significantly boosted by a $63.2 million gain from the change in fair value of 2023 Common Warrants, whereas the current period saw a $6.4 million gain in the same category.
- Liquidity: Cash and cash equivalents increased to $30.4 million as of June 30, 2026, up from $18.3 million at year-end 2025, aided by the maturity of short-term investments ($60.0 million) and the receipt of the Amoytop upfront payment (received in July 2026, though revenue recognized in Q2).
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. While cash on hand plus the Amoytop payment is expected to fund operations into the fourth quarter of 2026, the company requires substantial additional financing to continue operations beyond that period.
- Development Pipeline:
- Pevifoscorvir sodium: Phase 2 B-SUPREME study enrollment is complete; topline data expected in late Q3 2027. Received Fast Track Designation from FDA and Breakthrough Therapy Designation from China's NMPA.
- ALG-170675: Received IND approval in China; Phase 1 study expected to initiate in Q3 2026.
- ALG-055009: Phase 2a HERALD study met primary endpoint for liver fat reduction in MASH. Preclinical data suggests synergistic weight loss when combined with incretin receptor agonists.
- Key Risks:
- Capital Needs: Failure to secure additional funding could force the company to delay, limit, or terminate product development.
- Regulatory Uncertainty: Clinical trials are inherently uncertain; failure to demonstrate safety or efficacy could halt development.
- Trade and Geopolitics: Risks related to the U.S. BIOSECURE Act, potential tariffs on pharmaceuticals, and reliance on third-party manufacturers in China.
- Intellectual Property: Dependence on licensed IP from Emory University and KU Leuven; potential for infringement claims or loss of exclusivity.
Investor Verification Checklist
- Cash Runway: Verify the exact timeline for cash depletion and the status of any ongoing fundraising efforts to bridge the gap beyond Q4 2026.
- Amoytop Agreement Terms: Review the specific milestones and royalty rates in the $25M upfront license deal to understand future revenue potential and obligations.
- Phase 2 Trial Progress: Monitor enrollment and safety data for the pevifoscorvir sodium Phase 2 B-SUPREME study, as this is the primary value driver.
- Warrant Liability: Assess the volatility of the 2023 Common Warrants liability ($5.8 million) and its impact on future earnings due to fair value remeasurement.
- Regulatory Status: Confirm the status of IND approvals and any interactions with the FDA or NMPA regarding the clinical development plans.